Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown - PubMed

3 days ago

GLP1RAs are used for treating type 2 diabetes (T2DM) and obesity, both of which are linked to higher cancer risk.
Weight loss can reduce cancer risk in T2DM and obesity, but the effect of reducing hyperglycemia is uncertain.
GLP1RAs may have direct effects on cancer risk, potentially reducing some cancers (e.g., hepatocellular, endometrial) but raising concerns for thyroid cancers.
Initial concerns about pancreatic cancer risk with GLP1RAs have not been confirmed.
Current data limitations include detection/prescription biases in observational studies and insufficient follow-up in trials.
The risk-benefit profile of GLP1RAs remains favorable for T2DM and obesity patients, but caution is needed for low-risk individuals.
Potential use of GLP1RAs as adjuvant cancer therapy requires further investigation.

Hasty Briefsbeta